Swiss drug maker Novartis (NVS) said its Phase III trial of Signifor LAR therapy was more effective in controlling acromegaly disease compared to other existing therapies.
"These results strengthen our understanding of this rare endocrine disorder and suggest pasireotide LAR may offer benefit for acromegaly patients whose disease is not fully controlled on their current therapy. As part of our long-standing commitment to transforming the care of rare pituitary diseases, we are working to bring this potentially meaningful solution to the acromegaly community," said Alessandro Riva, president, Novartis Oncology ad interim and Global Head, Oncology Development and Medical Affairs.
AIIMS Doctors Remove Tumor Responsible for Gigantic Growth in Woman
Doctors at the All India Institute of Medical Sciences (AIIMS) have been able to 'cure' a 7.8 feet woman after removing a tumor.
Advertisement
Benign tumour in pituitary gland that secretes excess growth hormone leads to acromegaly that causes enlargement of body parts, including hands, feet and facial features.
The Phase III trial that was done on 198 patients examined pasireotide LAR 40 mg or pasireotide LAR 60 mg versus continued open-label treatment with octreotide LAR 30 mg or lanreotide Autogel 120 mg (the control group) for 24 weeks.
Source: Medindia
Source: Medindia
Potential Therapeutic Target for Cushing's Disease Identified
A protein that drives the formation of pituitary tumors in Cushing's disease has been discovered by scientists.
Advertisement
 Medicine Helps Short Children 'Rise in Stature' With Growth Hormone TherapyGrowth hormone therapy can significantly increase height in children with short stature, says a new study. | Advertisement
|
Advertisement
Recommended Reading
Latest Clinical Trials News
Amyotrophic lateral sclerosis patients' motor neurons responded robustly to Parkinson's drug ropinirole.
A new way to quickly eliminate fungal infections in the mouth has been developed by researchers at Penn Dental and Penn Engineering, using magnetically guided nanorobots.
Researchers tested the effectiveness of virus-mediated gene therapy for genetic hearing loss in an aged mouse model with genetic changes related to deafness.
The outcomes of the first clinical trial demonstrate the safety and efficacy of the measles-rubella (MR) vaccination to adults and infants as young as 9 months.
Scientists devise a fully integrated autonomous wearable ultrasonic-system-on-patch to sense deep tissue vital signs wirelessly even when the patient is on the move.